To investigate the efficacy of repetitive transcranial magnetic stimulation(rTMS) at different sites combined with escitalopram oxalate in patients with post-stroke depression(PSD).
The PSD patients admitted to the Affiliated Hospital of Shandong Second Medical University from June 2023 to March 2025 were selected as the research subjects. All subjects received treatment with escitalopram oxalate. They were divided into four groups by simple random sorting method: the drug group(group A), the left magnetic stimulation group[group B, high-frequency rTMS targeting the dorsolateral prefrontal cortex(DLPFC) on the left side], the right magnetic stimulation group(group C, low-frequency rTMS targeting the DLPFC on the right side), and the bilateral magnetic stimulation group(group D, bilateral rTMS), 31 patients in each group. All patients were treated continuously for 4 weeks. The scores of the Patient Health Questionnaire(PHQ)-9, the National Institutes of Health Stroke Scale(NIHSS), and Hamilton Depression Rating Scale 17-item(HAMD-17) were statistically analyzed before and after treatment. The levels of serum neuroendocrine-related markers[S100 calcium binding protein B subunit(S100β), 5-hydroxytryptamine(5-HT), neuron-specific enolase(NSE)], inflammatory factors[tumor necrosis factor(TNF)-α, interleukin(IL)-1β, IL-6], and sleep electroencephalogram parameters[sleep latency(SL), total sleep time(TST), sleep efficiency] were compared before and after treatment.
During the study period, some patients were excluded due to various reasons. Ultimately, 30 cases remained in group A, 29 cases in group B, 30 cases in group C, and 30 cases in group D. After treatment, the NIHSS, PHQ-9 and HAMD-17 scores, levels of S100β, NSE, IL-1β, TNF-α, and IL-6 in group D were lower than those of the other three groups, and group B and group C were lower than group A. The levels of 5-HT, TST, and sleep efficiency in the serum of group D were higher than those in the other three groups, and the levels in groups B and C were higher than those in group A. The serum IL-1β level in group B was lower than that in group C, and the serum TNF-α level in group C was lower than that in group B. The SL in group D was shorter than that of the other three groups, and the SL in groups B and C was shorter than that in group A. All of the above differences were statistically significant(P<0.05).
The combined treatment regimen of bilateral rTMS and escitalopram oxalate applied to patients with PSD can regulate neural functions and inflammatory factors, reduce depression levels, and improve neurological function and sleep quality.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |